People · Operator
Named in public records as an officer, director or promoter · active 2020–2020 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| ImmunoRx Pharma, Inc. | — | Pharmaceuticals | Seed | $2.7M | $82.2M | 2020 |
| Sarkana Pharma, Inc. | — | Pharmaceuticals | Seed | $1.6M | $47.0M | 2020 |
Mark Cipriano at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Cipriano on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Caroline Fortier | 2 | 2 |
| Luc Marengere | 1 | 2 |
| Marc Riviere | 1 | 1 |
| Philippe Tessier | 1 | 1 |
| Alexandre Lebeaut | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.